Cargando…

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017

OBJECTIVE: To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xingyue, Liu, Bao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301790/ http://dx.doi.org/10.1136/bmjopen-2021-058843

Ejemplares similares

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Publicado: (2018)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Compromise or Capitulation? US Food and Drug Administration Jurisdiction Over Tobacco Products
por: Glantz, Stanton A., et al.
Publicado: (2009)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

The US Food and Drug Administration Provides a Pathway for Licensing Vaccines for Global Diseases
por: Brennan, Michael J.
Publicado: (2009)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
por: Fan, Min, et al.
Publicado: (2022)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan
por: Okubo, TK, et al.
Publicado: (2017)

Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China
por: Kramer, Daniel B., et al.
Publicado: (2013)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

The association between US Food and Drug Administration−expedited review designations and health plan specialty drug coverage
por: Panzer, Ari D, et al.
Publicado: (2023)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014)

Expedited Development Programs at the Food and Drug Administration: Insights and Opportunities
por: Collins, Grace, et al.
Publicado: (2021)

A New Approach to Psychiatric Drug Approval in Europe
por: Barbui, Corrado, et al.
Publicado: (2013)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
por: Xie, Jinping, et al.
Publicado: (2023)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
por: Faucette, Stephanie, et al.
Publicado: (2017)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
por: Yu, Jingjing, et al.
Publicado: (2020)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pujnaq8b3j8or2mba3qn7t7f41